Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe 5mg Mounjaro KwikPen contains 80 units of tirzepatide in total — four weekly doses of 20 units each — at a concentration of 1mg per 4 units. That single pen covers one full month of treatment. Because the pen is pre-filled and pre-set, you never draw a dose yourself; the device delivers exactly 20 units (5mg) each week when the plunger is pressed fully. These are prescription-only medicines assessed individually by a clinician before they can be supplied, so the right dose for you is always a prescriber's call rather than a self-calculation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide's concentration in the Mounjaro KwikPen is standardised across all strengths at a ratio that sets 1mg equal to 4 units. At 5mg, that works out to 20 units per weekly dose. The full pen (three millilitres of solution) therefore contains 80 units in total, split into four equal doses.
This unit language comes from insulin practice, where syringes are calibrated in units rather than milligrams. If a patient, carer or healthcare professional ever cross-references the volume against a unit count, that 4-units-per-mg ratio is the conversion to use. For anyone moving from a vial-and-syringe protocol to the KwikPen, the arithmetic is the same; only the delivery method changes.
In day-to-day use, though, the figure is largely academic. The KwikPen does not have a dial you set to 20; it has a single plunger that, pressed firmly until it clicks and then held for ten seconds at the injection site, releases the entire 5mg dose. Our 5mg Mounjaro page covers the practical steps in more detail. The SmPC on the electronic Medicines Compendium is the authoritative reference for concentration and volume data if you need them for clinical documentation.
The starting pen in the tirzepatide schedule is 2.5mg. That pen delivers 10 units per weekly injection, again at the same 4-units-per-mg ratio. Moving to 5mg at week five doubles the weekly unit count to 20, but the mechanical experience is identical: one press of the plunger, one dose.
The escalation exists because tolerability matters more than speed. The body adjusts to GLP-1 and GIP receptor activity gradually, and stepping up through the schedule reduces the chance of significant nausea or GI discomfort. The 2.5mg pen's unit breakdown follows the same logic at half the dose. Higher strengths (7.5mg, 10mg, 12.5mg and 15mg) all use pens calibrated identically, so a 7.5mg dose is 30 units, and so on up the schedule.
Prescribers decide whether and when to increase the dose. The NHS page on tirzepatide explains the general titration approach clearly. What matters from your side is keeping to the once-weekly rhythm and storing the pen correctly, it lives in the fridge (2–8°C), and the door shelf works well as long as the temperature stays stable.
The maths is consistent (1mg equals 4 units throughout the Mounjaro range) so the arithmetic is simple enough. A 10-unit dose is 2.5mg; 30 units is 7.5mg; 60 units is 15mg. These conversions are useful context, particularly for patients who want to understand what they have been prescribed relative to other strengths.
What the conversion cannot tell you is whether a different dose is right for you. Tirzepatide is a prescription-only medicine and the NICE appraisal of tirzepatide (TA1026) makes clear that dose decisions sit with the prescribing clinician, accounting for weight loss response, tolerability and individual health history. Self-adjusting outside the agreed schedule is not recommended.
If you are researching costs alongside dosing, the Mounjaro cost page gives an honest account of how UK private pricing works by strength. For a broader look at where tirzepatide fits among available treatments, the weight-loss treatments overview is a useful starting point.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.